drugset / Trial / NCT05656027
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
Timeline
- Start
- 2022-12-19
- Primary completion
- 2023-12-15
- Completion
- 2024-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aceclidine | Small molecule | — | — |
| Subject | Brimonidine | Small molecule | — | — |